Summary & Overview

CPT 80351: Synthetic Cannabinoid Panel, Four to Six Analytes

CPT code 80351 represents a specialized toxicology laboratory assay that measures or detects four to six synthetic cannabinoids in a patient specimen. As synthetic cannabinoids continue to be implicated in emergent toxicology cases and public health surveillance, this assay supports clinical diagnosis, forensic evaluation, and treatment decisions. Nationally, availability and coverage of this panel affect access to targeted toxicology testing in emergency departments, inpatient settings, and outpatient laboratories. Key payers reviewed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose and service setting for CPT code 80351, payer coverage considerations, common billing modifiers, and the typical operational context for performing this test. The publication summarizes benchmark topics such as utilization drivers, coding and billing patterns, and where policy updates may influence laboratory billing practices. It also outlines what clinicians and billing professionals should know about the test’s clinical role in detecting emerging synthetic cannabinoid exposures and the administrative elements commonly associated with specialized toxicology assays. Data not available in the input is noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicare80351CPTtoxicologysynthetic cannabinoidslaboratory testingdrug screeningclinical laboratorytoxicology assay

Billing Code Overview

CPT code 80351 describes a laboratory procedure in which a lab analyst measures the amount of or detects the presence of four to six synthetic cannabinoids in a patient specimen. This service is a multi-analyte toxicology assay focused on synthetic cannabinoid compounds.

Service type: Laboratory testing for synthetic cannabinoids
Typical site of service: Clinical laboratory or hospital laboratory performing specialized toxicology testing

Clinical & Coding Specifications

Clinical Context

A 28-year-old emergency department patient presents with acute agitation, altered mental status, and atypical vital signs after possible ingestion of a synthetic cannabinoid product. The ED clinician obtains a urine specimen and orders a targeted toxicology panel to detect synthetic cannabinoids. The specimen is sent to the hospital laboratory or a reference lab where a clinical laboratory scientist performs qualitative and/or semi-quantitative analysis for four to six synthetic cannabinoid analytes using validated methods (for example, liquid chromatography–mass spectrometry). The workflow includes specimen accessioning, chain-of-custody documentation if required for legal/forensic cases, specimen preparation, analytical testing, result verification by a laboratory director, and reporting to the ordering clinician. Results inform acute management (supportive care, toxicology consultation, observation) and, when applicable, occupational, forensic, or public health reporting.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier (default)	Routine billing when no specific modifier applies.
`26`	Professional component	Use when billing only the laboratory interpretation/medical direction separate from technical testing.
`TC`	Technical component	Use when billing only the laboratory technical component (instrumentation, reagents, technician time).
`90`	Reference laboratory	Use when the service is performed by an outside (reference) laboratory and billed by the ordering facility.
`52`	Reduced services	Use when the test is partially performed or limited relative to full service.
`53`	Discontinued procedure	Use if testing was begun but discontinued for clinical reasons prior to completion.
`59`	Distinct procedural service	Note: `59` is not listed in input modifiers; not applicable.
`90`	(Duplicate entry omitted)	(See above)
`62`	Two surgeons	Not typically applicable to laboratory testing; include only if clinical oversight involves co-surgery billing (rare).
`78`	Unplanned return to OR	Not applicable to this lab service; avoid using for this code.
`AS`	Armed security/acute facility?	Input includes `AS` modifier code; typically denotes Physician assistant/assistant surgeon in some payer systems — not commonly used for lab testing.

Taxonomy Code	Specialty	Notes
`0000X`	Clinical Pathology / Medical Laboratory Director	Physicians board-certified in pathology or clinical pathology oversee testing and result validation.
`1835P0200X`	Clinical Laboratory Technologist	Laboratory professionals performing analytic testing and sample processing.
`2080S0120X`	Toxicology Specialist	Consulting toxicologists who interpret complex synthetic cannabinoid panels.
`207K00000X`	Emergency Medicine	Ordering clinicians in acute care settings initiating the test.

Note: Use of professional (26) and technical (TC) component modifiers is common to separate laboratory analytic and interpretation billing. Use 90 when services are performed by a reference lab. Modifiers that denote surgical events or anesthesia are generally not applicable to this laboratory procedure and should not be used.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`R41.0`	Disorientation, unspecified	Synthetic cannabinoid intoxication can present with altered mental status and disorientation prompting testing.
`F11.129`	Opioid abuse with intoxication, uncomplicated	Polysubstance use is common; clinicians may test for multiple agents including synthetic cannabinoids when patients present with intoxication.
`T40.7X5A`	Poisoning by other synthetic narcotics, accidental (initial encounter)	Synthetic cannabinoid exposure may be coded under poisoning/synthetic narcotic categories depending on documentation.
`R45.1`	Restlessness and agitation	Agitation is a frequent clinical presentation leading to ordering of toxicology panels for synthetic cannabinoids.
`F19.10`	Other psychoactive substance abuse, uncomplicated	May be used when synthetic cannabinoid use is documented without complications and substance-specific codes are not available.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`80351`	Synthetic cannabinoid analysis; detection of 4–6 synthetic cannabinoids	Primary procedure: analytic detection of four to six synthetic cannabinoids in a patient specimen.
`80307`	Drug confirmation, each specimen (for drugs of abuse), using chromatography/mass spectrometry techniques	Often performed when screening tests are positive and confirmation by definitive methods is required.
`80306`	Drug screening; each drug class by immunoassay (e.g., urine drug screen)	Commonly performed prior to or alongside specific synthetic cannabinoid testing as an initial broad screen.
`80320`	Ethyl alcohol analysis for legal/forensic purposes	May be performed concurrently in altered mental status cases to assess for concurrent alcohol intoxication.
`80305`	Drug screen, qualitative; multiple drug classes by immunoassay	An initial broad panel that can prompt targeted synthetic cannabinoid testing when results suggest designer drug exposure.